Business model
Alethia's business model is predicated on bringing its therapeutics from the laboratory through pre-clinical testing, IND filing, and Phase I and II clinical trials. The Company intends to pursue an aggressive product and business development strategy in order to be in position to negotiate high value licensing agreements with multinational biopharmaceutical companies, for its therapeutic compounds having demonstrated proof of efficacy in humans.
To fully exploit the potential of its discovery platform and to generate revenues to be re-invested in the Company's research programs, Alethia intends to license-out selected validated therapeutic targets and establish early stage drug discovery collaborations in other therapeutic fields.
Finally, Alethia's management would consider any other strategic initiatives aimed at expanding its clinical stage product portfolio and/or creating tactical critical mass in order to accelerate value creation for its shareholders.
